Stem cell investigation最新文献

{"title":"Novel Human Umbilical Di-Chimeric (HUDC) cell therapy for transplantation without life-long immunosuppression.","authors":"Maria Siemionow,&nbsp;Joanna Cwykiel,&nbsp;Lucile Chambily,&nbsp;Stephanie Gacek,&nbsp;Sonia Brodowska","doi":"10.21037/sci-2023-024","DOIUrl":"https://doi.org/10.21037/sci-2023-024","url":null,"abstract":"<p><strong>Background: </strong>Cell-based therapies are promising for tolerance induction in bone marrow (BM), solid organs, and vascularized composite allotransplantation (VCA). The toxicity of bone marrow transplantation (BMT) protocols precludes this approach from routine clinical applications. To address this problem, we developed a new therapy of Human Umbilical Di-Chimeric (HUDC) cells for tolerance induction in transplantation. This study established <i>in vitro</i> characterization of the created HUDC cells.</p><p><strong>Methods: </strong>We performed sixteen <i>ex vivo</i> polyethylene glycol (PEG)-mediated fusions of human umbilical cord blood (UCB) cells from two unrelated donors. Fusion feasibility was confirmed <i>in vitro</i> by flow cytometry (FC) and confocal microscopy (CM). The HUDC cells' genotype was assessed by lymphocytotoxicity test and short tandem repeat-polymerase chain reaction (STR-PCR) analysis, phenotype by FC, viability by LIVE/DEAD^® assay, and apoptosis level by Annexin V staining. We used COMET assay to assess HUDC cells' genotoxicity after the fusion procedure. Clonogenic properties of HUDC cells were evaluated by colony forming unit (CFU) assay. Mixed lymphocyte reaction (MLR) assay assessed immunogenic and tolerogenic properties of HUDC cells.</p><p><strong>Results: </strong>We confirmed the creation of HUDC cells from two unrelated human donors of UCB cells by FC and CM. Human leukocyte antigen (HLA) class I and II typing, and STR-PCR analysis of HUDC cells confirmed the presence of alleles and loci from both unrelated UCB donors (donor chimerism: 49%±8.3%, n=4). FC confirmed the hematopoietic phenotype of HUDC cells. We confirmed high HUDC cells' viability (0.47% of dead cells) and a low apoptosis level of fused HUDC cells (15.9%) compared to positive control of PKH-stained UCB cells (20.4%) before fusion. COMET assay of HUDC cells revealed a lack of DNA damage. CFU assay confirmed clonogenic properties of HUDC cells, and MLR assay revealed a low immunogenicity of HUDC cells.</p><p><strong>Conclusions: </strong>This study confirmed creation of a novel HUDC cell line by <i>ex vivo</i> PEG-mediated fusion of UCB cells from two unrelated donors. The unique concept of creating a HUDC cell line, representing the genotype and phenotype of both, transplant donor and the recipient, introduces a promising approach for tolerance induction in BM, solid organs, and VCA transplantation.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/c5/sci-10-2023-024.PMC10442563.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10063590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide.","authors":"Manuel Espinoza-Gutarra,&nbsp;Ayman Saad,&nbsp;Omer Jamy","doi":"10.21037/sci-2023-002","DOIUrl":"https://doi.org/10.21037/sci-2023-002","url":null,"abstract":"","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/0f/sci-10-2023-002.PMC10098427.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9309525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunophenotypic analysis of human adipose-derived stem cells through multi-color flow cytometry.","authors":"Paolo Giuseppe Limoli,&nbsp;Marcella Nebbioso","doi":"10.21037/sci-2023-010","DOIUrl":"https://doi.org/10.21037/sci-2023-010","url":null,"abstract":"","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/1c/sci-10-2023-010.PMC10266955.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9654995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary central nervous system lymphoma: treatment access and outcomes in HIV positive patients in a minority rich cohort.","authors":"Hiba Narvel,&nbsp;Charan Vegivinti,&nbsp;Sindhu Vikash,&nbsp;Abdul Hamid Bazarbachi,&nbsp;Kith Pradhan,&nbsp;Shuai Wang,&nbsp;M Bakri Hammami,&nbsp;Nida Narvel,&nbsp;Shreyas Yakkali,&nbsp;Shehbaz Ansari,&nbsp;Adnan Gulam Nabi,&nbsp;Turab Mohammed,&nbsp;Ioannis Mantzaris,&nbsp;Marina Konopleva,&nbsp;Mendel Goldfinger,&nbsp;Kira Gritsman,&nbsp;Dennis Cooper,&nbsp;Aditi Shastri,&nbsp;Nishi Shah,&nbsp;Noah Kornblum,&nbsp;Amit Verma,&nbsp;R Alejandro Sica","doi":"10.21037/sci-2023-021","DOIUrl":"https://doi.org/10.21037/sci-2023-021","url":null,"abstract":"","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/71/sci-10-2023-021.PMC10468403.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and prospects of regenerative medicine for spinal cord injury using human induced pluripotent stem cells: a review.","authors":"Mitsuhiro Inoue,&nbsp;Ryo Yamaguchi,&nbsp;Ching Chi Jimmy He,&nbsp;Atsushi Ikeda,&nbsp;Hideyuki Okano,&nbsp;Jun Kohyama","doi":"10.21037/sci-2022-037","DOIUrl":"https://doi.org/10.21037/sci-2022-037","url":null,"abstract":"<p><p>Spinal cord injury (SCI) is damage to the spinal cord due to trauma or health conditions, resulting in lesions in the spinal cord. Currently, available treatment includes surgical intervention to decompress or stabilize a dislocated loose spine, steroid drugs to reduce inflammation, and subsequent rehabilitation. As there is a rising number of SCI globally, radical treatments to recover spinal cord functions have become highly anticipated. The development of new treatments is indeed progressing. Various therapeutic drug candidates are being developed in clinical trials, including neuroprotective/neurotrophic factors, antibodies for repulsive guidance molecules, and cell transplantation. Among them, with advances in stem cell biology, cell transplantation therapy is currently a promising therapeutic development for SCI. In particular, there have been various reports regarding the realization of regenerative medicine using human induced pluripotent stem cells (iPSCs). This review will introduce the advantages of cell-based therapy based on iPSC-derived neural stem/progenitor cells (iPSC-NS/PCs) and some of their mechanisms of action for functional improvement, which have recently been elucidated. Potential challenges and methodologies to realize the clinical application of iPSC-NS/PCs not only for the subacute phase but also for the chronic phase of SCI will be presented. Finally, we also introduce recent research with a view to the clinical application of spinal cord regenerative therapy and discuss future prospects.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/19/sci-10-2022-037.PMC10036917.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9192478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurogenic marker expression in differentiating human adipose derived adult mesenchymal stem cells.","authors":"Neus Gomila Pelegri,&nbsp;Bruce K Milthorpe,&nbsp;Catherine A Gorrie,&nbsp;Jerran Santos","doi":"10.21037/sci-2022-015","DOIUrl":"https://doi.org/10.21037/sci-2022-015","url":null,"abstract":"<p><strong>Background: </strong>Adipose-derived stem cells (ADSCs) are increasingly utilised in the field of neural regeneration due to their high accessibility and capacity for differentiation into neural like cells. Culturing ADSCs in the presence of various growth factors, small molecules and combinations thereof have shown promise in this regard; however, these protocols are generally complex, time-consuming and costly. The need for commercially available and chemically defined growth media/supplements is required to facilitate further developments in this area.</p><p><strong>Methods: </strong>In this study, we have examined the neural differentiation and proliferation potential of the commercially available supplements B27, CultureOne (C1) and N2 on human ADSCs (hADSCs). Through a combination of immunocytochemistry, cytokine analysis, and CNPase enzymatic assays, we provide novel insight into the neural differentiation effects of B27, C1 and N2 on hADSCs.</p><p><strong>Results: </strong>The study found that C1 and N2 supplements initiated neural differentiation of the cells, with C1 pushing differentiation towards an oligodendrocytic lineage and N2 initiating neuronal differentiation. This suggests that C1 and N2 supplements can be used to drive neural differentiation in hADSCs. However, B27 did not show significant differentiation in the time frame in which the experiments took place and therefore is unsuitable for this purpose.</p><p><strong>Conclusions: </strong>These findings highlight the utility of commercially available supplements in the neural differentiation of ADSCs and may assist in establishing simpler, more affordable differentiation protocols.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/3c/sci-10-2022-015.PMC10076228.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9272299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recreating heterogeneity of bladder cancer microenvironment to study its recurrences and progression.","authors":"François Bordeleau,&nbsp;David Brownell,&nbsp;Stephane Chabaud,&nbsp;Marc-Etienne Huot,&nbsp;Stephane Bolduc","doi":"10.21037/sci-2023-004","DOIUrl":"https://doi.org/10.21037/sci-2023-004","url":null,"abstract":"forms are treated by a radical cystectomy, which consists in removing the entire bladder but sometimes also the surrounding tissues (6). It should be noted that recurrences after treatment will occur in 80% of non-invasive BCa cases, which can then progress to an invasive form in 30% of patients (7). In the last three decades, no significant improvement resulted from research to reduce the mortality of the BCa. Immunotherapy has recently raised hopes, but the results still seem limited, even if they may in the future","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/5e/sci-10-2023-004.PMC9995704.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9470046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Femur bone marrow from brain death deceased donors as source of human mesenchymal stromal cells for cell therapy.","authors":"Lourdes Echarte,&nbsp;Alexandra Sujanov,&nbsp;Daniel Machin,&nbsp;Natalia Marquisá,&nbsp;Cristina Touriño","doi":"10.21037/sci-2023-003","DOIUrl":"https://doi.org/10.21037/sci-2023-003","url":null,"abstract":"<p><strong>Background: </strong>The use of a deceased donor (DD) as an alternative source of human mesenchymal stromal cells (hMSC) is promising, but has been little explored. This study evaluated the potential of femur bone marrow (FBM) from brain-death donors as a source of hMSC and compared this with hMSC from matched iliac crest bone marrow (ICBM).</p><p><strong>Methods: </strong>Sixteen donor-matched FBM and ICBM samples were processed from brain-death donors. We analyzed the starting material and compared cell yield, phenotypic profile and differentiation capacity of hMSC.</p><p><strong>Results: </strong>Neither the amount of nucleated cells per gram (14.6×10⁶±10.3×10⁶ from FBM <i>vs.</i> 38.8×10⁶±34.6×10⁶ from ICBM, P≥0.09) nor the frequency of CFU-F (0.0042%±0.0036% in FBM <i>vs.</i> 0.0057%±0.0042% in ICBM, P≥0.73) differ significantly from FBM or ICBM. Cell cultures from both sources were obtained and hMSC yields showed that there were no significant differences in hMSC obtained per gram of bone marrow (BM) when comparing femur with iliac crest samples. At passage 2, 12.5×10⁶±12.9×10⁶ and 5.0×10⁶±4.4×10⁶ hMSC per gram of BM were obtained from FBM and ICBM, respectively. FBM and ICBM hMSC express CD73, CD90, CD105, but not hematopoietic lineage markers [CD45, CD34, CD11, CD19 and isotype of HLA clase II (HLA-DR)]. HLA-A expression from both sources was clearly detected, while HLA-B was weakly expressed or undetectable and HLA-DR was undetectable. Cells from both sources were differentiated <i>in vitro</i> into osteoblasts, adipocytes and chondroblasts.</p><p><strong>Conclusions: </strong>To our knowledge, there are no previous studies evaluating BM from femur dead donors as a source of hMSC. Our findings confirm that it is feasible to expand cells from FBM from brain-death donors meeting <i>in vitro</i> characteristics of hMSC, making them a promising source for clinical translation.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/49/sci-10-2023-003.PMC10248827.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events, side effects and complications in mesenchymal stromal cell-based therapies.","authors":"Denis S Baranovskii,&nbsp;Ilya D Klabukov,&nbsp;Nadezhda V Arguchinskaya,&nbsp;Anna O Yakimova,&nbsp;Anastas A Kisel,&nbsp;Elena M Yatsenko,&nbsp;Sergei A Ivanov,&nbsp;Peter V Shegay,&nbsp;Andrey D Kaprin","doi":"10.21037/sci-2022-025","DOIUrl":"https://doi.org/10.21037/sci-2022-025","url":null,"abstract":"<p><p>Numerous clinical studies have shown a wide clinical potential of mesenchymal stromal cells (MSCs) application. However, recent experience has accumulated numerous reports of adverse events and side effects associated with MSCs therapy. Furthermore, the strategies and methods of MSCs therapy did not change significantly in recent decades despite the clinical impact and awareness of potential complications. An extended understanding of limitations could lead to a wider clinical implementation of safe cell therapies and avoid harmful approaches. Therefore, our objective was to summarize the possible negative effects observed during MSCs-based therapies. We were also aimed to discuss the risks caused by weaknesses in cell processing, including isolation, culturing, and storage. Cell processing and cell culture could dramatically influence cell population profile, change protein expression and cell differentiation paving the way for future negative effects. Long-term cell culture led to accumulation of chromosomal abnormalities. Overdosed antibiotics in culture media enhanced the risk of mycoplasma contamination. Clinical trials reported thromboembolism and fibrosis as the most common adverse events of MSCs therapy. Their delayed manifestation generally depends on the patient's individual phenotype and requires specific awareness during the clinical trials with obligatory inclusion in the patient' informed consents. Finally we prepared the safety checklist, recommended for clinical specialists before administration or planning of MSCs therapy.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/a8/sci-09-2022-025.PMC9659480.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40482408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report.","authors":"Yubin Kang, Andrew J Armstrong, David S Hsu","doi":"10.21037/sci-2022-029","DOIUrl":"10.21037/sci-2022-029","url":null,"abstract":"<p><strong>Background: </strong>There is an unmet need for developing faithful animal models for preclinical evaluation of immunotherapy. The current approach to generate preclinical models for immunotherapy evaluation has been to transplant CD34⁺ cells from umbilical cord blood into immune-deficient mice followed by implantation of patient derived tumor cells. However, current models are associated with high tumor rejection rate secondary to the allograft <i>vs.</i> tumor response from human leukocyte antigen (HLA) mismatches. We herein report the first development of a novel, humanized patient-derived xenograft (PDX) model using autologous CD34⁺ cells from bone marrow aspirate obtained from a patient with metastatic clear cell renal cell carcinoma (mRCC) from whom a PDX had been developed.</p><p><strong>Case description: </strong>This is a 68-year-old Caucasian man diagnosed with mRCC with metastasis to the liver in 2014. He was treated with sunitinib +/- AGS-003 and underwent a cytoreductive right nephrectomy, left adrenalectomy and partial liver resection. PDX was generated using resected nephrectomy specimen. After surgery, patient received multiple lines of standard of care therapy including sunitinib, axitinib, bevacizumab, everolimus and cabozantinib. While progressing on cabozantinib, he was treated with nivolumab. Seven years after initiation of nivolumab, and 4 years after stopping systemic therapy, he remains in complete remission. To generate autologous PDX model, bone marrow aspirate was performed and CD34⁺ hematopoietic stem/progenitor cells (HSPCs) were isolated and injected into 150 rad irradiated non-obese diabetic scid gamma null (NSG) mice. At 11 weeks post-transplant, the matched patient PDX was injected subcutaneously into the humanized mice and the mice were treated with nivolumab.</p><p><strong>Conclusions: </strong>Our case represents successful therapy of nivolumab in mRCC. Furthermore, HPSCs obtained from a single bone marrow aspirate were able to reconstitute an immune system in the mice that allowed nivolumab to inhibit the tumor growth of PDX and recapitulated the durable remission observed in the patient with nivolumab. We observed the reconstitution of human T cells, B cells and natural killer (NK) cells and unlike the humanized mouse model using cord blood, our model system eliminates the tumor rejection from mis-matched HLA. Our autologous humanized renal cell carcinoma (RCC) PDX model provides an effective tool to study immunotherapy in a preclinical setting.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/59/sci-09-2022-029.PMC9659479.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9650449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}